Frontline Management of Anemia in Lower-Risk Myelodysplastic Syndromes: Updates and Insights for Pharmacists

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Bristol Myers Squibb.

Registration & Dates for Activities

Wednesday, October 23, 2024
2:00-2:30 PM ET

FACULTY

Anthony J. Perissinotti, PharmD, BCOP
Clinical Pharmacist Specialist, Inpatient Hematology
Clinical Team Lead - Hematology/Oncology
University of Michigan - Michigan Medicine
Ann Arbor, Michigan

FINANCIAL DISCLOSURE

Dr. Perissinotti has disclosed that he has served as a consultant for Abbvie, Amgen, and Servier.

The clinical reviewer, Lisa Holle, PharmD, BCOP, FHOPA has no actual or potential conflicts of interest in relation to this program.

Susanne Batesko, MSHF, BSN, RN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

All relevant financial relationships have been mitigated.

ACCREDITATION STATEMENTS

PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-24-051-L01-P
Credits: 0.5 hour (0.05 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee. This is a free continuing education activity.
Estimated time to complete activity: 30 minutes

TARGET AUDIENCE

This accredited activity has been designed for oncology, managed care, and specialty pharmacists.

HOW TO OBTAIN CREDIT

Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.

GOAL

The goal of this PowerUp Live Q&A session is to provide learners the opportunity to ask the faculty questions about frontline management of anemia in Lower-Risk Myelodysplastic Syndromes.

For a more in-depth review of this topic, we recommend that you view the faculty’s CE monograph titled, Frontline Management of Anemia in Lower-Risk Myelodysplastic Syndromes: Updates and Insights for Pharmacists available at https://www.powerpak.com/course/preamble/125075, (expires November 20, 2024)

EDUCATIONAL OBJECTIVES

Upon completion of this activity, the participant should be able to:

• Discuss the limitations of managing lower-risk disease with traditional supportive care and recent therapeutic updates involving the frontline management of anemia among lower-risk MDS patients
• Explain optimal approaches for mitigating adverse events associated with newer treatment options for anemia in patients with lower-risk MDS

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Bristol Myers Squibb. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities. The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA.